Compare PMM & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMM | PROF |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 238.1M |
| IPO Year | N/A | 2017 |
| Metric | PMM | PROF |
|---|---|---|
| Price | $6.23 | $5.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 111.4K | ★ 232.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | 0.23 | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | $27.22 | ★ $4.57 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $5.70 | $3.92 |
| 52 Week High | $6.52 | $8.95 |
| Indicator | PMM | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 45.70 |
| Support Level | $6.07 | $5.81 |
| Resistance Level | $6.36 | $5.98 |
| Average True Range (ATR) | 0.09 | 0.49 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 83.74 | 49.19 |
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.